[Renin-angiotensin system in atherosclerosis]

Daiju Fukuda1, Masataka Sata

  • 1Department of Cardiovascular Medicine, University of Tokyo.

Insights

The renin-angiotensin system (RAS) drives atherosclerosis and cardiovascular disease by producing Angiotensin II (Ang II). Ang II promotes inflammation and oxidative stress, offering potential therapeutic targets.

Area of Science:

  • Cardiovascular Science
  • Endocrinology
  • Pathophysiology

Context:

  • The renin-angiotensin system (RAS) is implicated in cardiovascular diseases.
  • Angiotensin II (Ang II), a key RAS component, contributes to atherosclerosis.
  • Local RAS within the vasculature plays a significant role.

Purpose:

  • To investigate the role of reactive oxygen species (ROS) and inflammation in RAS-mediated atherogenesis.
  • To elucidate the mechanisms by which Ang II contributes to atherosclerotic development.

Summary:

  • Angiotensin II (Ang II) promotes atherosclerosis through endothelial dysfunction, cellular proliferation, and inflammation.
  • Reactive oxygen species (ROS) mediate many of the atherogenic effects of Ang II.
  • The local RAS in the vasculature is a critical factor in disease progression.

Impact:

  • Understanding RAS-induced ROS and inflammation can clarify atherosclerotic pathophysiology.
  • This research may reveal novel therapeutic strategies for atherosclerotic diseases.

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...